Passively administered monoclonal antibodies (mAbs) given before or after viral infection
can prevent or blunt disease. Here, we examine the efficacy of aerosol mAb delivery to …

Despite the success of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
vaccines, there remains a need for more prevention and treatment options for individuals …

Although SARS-CoV-2-neutralizing antibodies are promising therapeutics against COVID-
19, little is known about their mechanism (s) of action or effective dosing windows. We report …

There is an urgent need for effective therapeutic interventions against SARS-CoV-2,
including new variants that continue to arise. Neutralizing monoclonal antibodies have …

The severe acute respiratory syndrome (SARS-CoV-2), a newly emerging of coronavirus,
continues to infect humans in the absence of a viable treatment. Neutralizing antibodies that …

The respiratory system, especially the lung, is the key site of pathological injury induced by
SARS-CoV-2 infection. Given the low feasibility of targeted delivery of antibodies into the …

SARS-CoV-2 poses a public health threat for which therapeutic agents are urgently needed.
Herein, we report that high-throughput microfluidic screening of antigen-specific B-cells led …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still rapidly spreading
worldwide. Many drugs and vaccines have been approved for clinical use show efficacy in …

The persistence of the global severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐
2) pandemic has brought to the forefront the need for safe and effective vaccination …

ABSTRACT SARS-CoV-2, the causative agent of COVID-191, recognizes host cells by
attaching its receptor-binding domain (RBD) to the host receptor ACE22-7. Neutralizing …